随机安慰剂对照SENSCIS试验中接受尼达尼布治疗的系统性硬化症相关间质性肺病患者营养不良风险
在SENSCIS随机对照试验中,按基线BMI≤20 kg/m2与>20 kg/m2分层评估接受尼达尼布或安慰剂治疗的SSc-ILD患者52周内的不良事件与营养不良风险。尼达尼布的不良事件特征在两个BMI亚组间相似;多数患者维持低营养不良风险,但尼达尼布组末次评估时由低风险转为高风险的比例高于安慰剂组。
要点
- 尼达尼布的不良事件特征在基线BMI≤20 kg/m2(n=61)与>20 kg/m2(n=515)亚组间相似。
- 基于改良MUST,尼达尼布组末次评估时由低风险转为高风险者占4.5%,安慰剂组占1.0%。
- 作者认为管理可能与体重下降相关的疾病表现和不良事件对降低SSc-ILD患者营养不良风险很重要。
核心结论
- 在SENSCIS试验中,多数SSc-ILD患者在52周内维持低营养不良风险,但接受尼达尼布治疗者中高风险比例高于接受安慰剂者。
- 作者认为,管理可能与体重下降相关的疾病表现和不良事件对降低SSc-ILD患者营养不良风险很重要。
研究设计与样本
- SENSCIS随机、安慰剂对照试验中随机接受尼达尼布或安慰剂治疗的SSc-ILD患者,按基线BMI≤20 kg/m2和>20 kg/m2分层评估不良事件,并用改良版营养不良通用筛查工具(MUST)评估52周内营养不良风险。
主要发现
- 尼达尼布的不良事件特征在基线BMI≤20 kg/m2(n=61)与>20 kg/m2(n=515)亚组间相似。
- 基线BMI≤20 kg/m2与>20 kg/m2亚组中,不良事件导致停药者分别占尼达尼布组16.7%与15.9%、安慰剂组13.5%与8.0%。
- 基于改良MUST,基线与末次评估均为低营养不良风险者尼达尼布组占74.0%、安慰剂组占78.1%。
- 基于改良MUST,基线低风险而末次评估为高风险者尼达尼布组占4.5%、安慰剂组占1.0%。
临床怎么用
- 作者认为,管理可能与体重下降相关的疾病表现和不良事件对降低SSc-ILD患者营养不良风险很重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess adverse events (AEs) in relation to baseline body mass index (BMI) and the risk of malnutrition in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with nintedanib. METHODS: Among patients with SSc-ILD randomized to receive nintedanib or placebo in the SENSCIS trial, we assessed AEs in subgroups by baseline BMI ≤20 kg/m2 and BMI >20 kg/m2 , and the risk of malnutrition using a modified version of the Malnutrition Universal Screening Tool (MUST), over 52 weeks. RESULTS: The AE profile of nintedanib was similar between subgroups with a baseline BMI ≤20 kg/m2 (n = 61) and a baseline BMI >20 kg/m2 (n = 515). In these subgroups, respectively, AEs led to treatment discontinuation in 16.7% and 15.9% of the nintedanib group and 13.5% and 8.0% of the placebo group, respectively. Based on the modified MUST, the proportions of patients who had a low risk of malnutrition at baseline and at their last assessment were 74.0% in the nintedanib group and 78.1% in the placebo group, while the proportions who were classified as at low risk at baseline but at high risk by their last assessment were 4.5% in the nintedanib group and 1.0% in the placebo group. CONCLUSION: In the SENSCIS trial, most patients with SSc-ILD remained at low risk of malnutrition over 52 weeks, but the proportion at high risk was higher in patients who received treatment with nintedanib compared to those who received placebo. Management of disease manifestations and AEs that may be associated with weight loss is important to reduce the risk of malnutrition in patients with SSc-ILD.
引用
- Volkmann ER, McMahan ZH, Smith V, et al. Risk of Malnutrition in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo-Controlled SENSCIS Trial. Arthritis Care Res (Hoboken). 2023. PMID: 37357024. doi:10.1002/acr.25176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。